What is D+R Lathian?
Established in 1999, D+R Lathian operates as a critical nexus between life science organizations and healthcare providers. The company leverages its proprietary MyDrugRep.com platform to deliver high-impact branded and unbranded medical content. With a footprint spanning 20 therapeutic categories and supporting over 115 distinct brands, the firm utilizes a sophisticated omnichannel approach that integrates digital and print marketing tactics. Their ability to maintain engagement rates that consistently outperform industry benchmarks has made them a preferred partner for over 60 life sciences companies, effectively bridging the communication gap for more than 806,000 physicians.
How much funding has D+R Lathian raised?
D+R Lathian has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in D+R Lathian
PPP
Public-Private Partnership
What's next for D+R Lathian?
With the recent influx of capital, D+R Lathian is poised to enter a new phase of operational expansion. The strategic roadmap likely involves enhancing the technological capabilities of the MyDrugRep.com ecosystem to further personalize physician engagement. As the healthcare marketing industry shifts toward more data-centric and automated solutions, D+R Lathian is expected to leverage its deep historical data and established network to capture additional market share. Future growth will likely focus on deepening integration with existing life science clients while exploring new therapeutic verticals to maintain its competitive edge in a rapidly evolving digital health environment.
See full D+R Lathian company page
